Literature DB >> 28551709

The Validity of a New Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for Evaluating Symptoms in the Clinical Setting.

N A Koloski1,2,3, M Jones4, J Hammer1,2, M von Wulffen1,2, A Shah1,2, H Hoelz1, M Kutyla1, D Burger1, N Martin1, S R Gurusamy1, N J Talley3, G Holtmann5,6,7.   

Abstract

BACKGROUND: The clinical assessments of patients with gastrointestinal symptoms can be time-consuming, and the symptoms captured during the consultation may be influenced by a variety of patient and non-patient factors. To facilitate standardized symptom assessment in the routine clinical setting, we developed the Structured Assessment of Gastrointestinal Symptom (SAGIS) instrument to precisely characterize symptoms in a routine clinical setting. AIMS: We aimed to validate SAGIS including its reliability, construct and discriminant validity, and utility in the clinical setting.
METHODS: Development of the SAGIS consisted of initial interviews with patients referred for the diagnostic work-up of digestive symptoms and relevant complaints identified. The final instrument consisted of 22 items as well as questions on extra intestinal symptoms and was given to 1120 consecutive patients attending a gastroenterology clinic randomly split into derivation (n = 596) and validation datasets (n = 551). Discriminant validity along with test-retest reliability was assessed. The time taken to perform a clinical assessment with and without the SAGIS was recorded along with doctor satisfaction with this tool.
RESULTS: Exploratory factor analysis conducted on the derivation sample suggested five symptom constructs labeled as abdominal pain/discomfort (seven items), gastroesophageal reflux disease/regurgitation symptoms (four items), nausea/vomiting (three items), diarrhea/incontinence (five items), and difficult defecation and constipation (2 items). Confirmatory factor analysis conducted on the validation sample supported the initially developed five-factor measurement model ([Formula: see text], p < 0.0001, χ 2/df = 4.6, CFI = 0.90, TLI = 0.88, RMSEA = 0.08). All symptom groups demonstrated differentiation between disease groups. The SAGIS was shown to be reliable over time and resulted in a 38% reduction of the time required for clinical assessment.
CONCLUSIONS: The SAGIS instrument has excellent psychometric properties and supports the clinical assessment of and symptom-based categorization of patients with a wide spectrum of gastrointestinal symptoms.

Entities:  

Keywords:  Gastrointestinal symptoms; Irritable bowel syndrome; Quality of life; Questionnaire development; Validation

Mesh:

Year:  2017        PMID: 28551709     DOI: 10.1007/s10620-017-4599-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Intensity of Chronic Pain--The Wrong Metric?

Authors:  Jane C Ballantyne; Mark D Sullivan
Journal:  N Engl J Med       Date:  2015-11-26       Impact factor: 91.245

2.  Guidelines--Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders.

Authors: 
Journal:  J Gastrointestin Liver Dis       Date:  2006-09       Impact factor: 2.008

Review 3.  Systematic review: health-related quality of life (HRQOL) questionnaires in gastro-oesophageal reflux disease.

Authors:  O Chassany; G Holtmann; J Malagelada; U Gebauer; H Doerfler; K Devault
Journal:  Aliment Pharmacol Ther       Date:  2008-03-20       Impact factor: 8.171

Review 4.  Systematic Review of the Clinical Disease Severity Indices for Inflammatory Bowel Disease.

Authors:  Laith Alrubaiy; Ibtihal Rikaby; Mohamed Sageer; Hayley Anne Hutchings; John Gordon Williams
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

5.  Framework to assess the effects of using patient-reported outcome measures in chronic care management.

Authors:  Maria-Jose Santana; David Feeny
Journal:  Qual Life Res       Date:  2013-12-07       Impact factor: 4.147

6.  The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study.

Authors:  N A Koloski; M Jones; J Kalantar; M Weltman; J Zaguirre; N J Talley
Journal:  Gut       Date:  2012-01-10       Impact factor: 23.059

7.  Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials.

Authors:  B M R Spiegel; R Bolus; N Agarwal; G Sayuk; L A Harris; S Lucak; E Esrailian; W D Chey; A Lembo; H Karsan; K Tillisch; J Talley; L Chang
Journal:  Aliment Pharmacol Ther       Date:  2010-09-28       Impact factor: 8.171

8.  Shape shifting pain: chronification of back pain shifts brain representation from nociceptive to emotional circuits.

Authors:  Javeria A Hashmi; Marwan N Baliki; Lejian Huang; Alex T Baria; Souraya Torbey; Kristina M Hermann; Thomas J Schnitzer; A Vania Apkarian
Journal:  Brain       Date:  2013-09       Impact factor: 13.501

Review 9.  Clinical assessment of irritable bowel syndrome.

Authors:  Tony J Lembo; Rebecca N Fink
Journal:  J Clin Gastroenterol       Date:  2002-07       Impact factor: 3.062

10.  Evaluation of model fit in nonlinear multilevel structural equation modeling.

Authors:  Karin Schermelleh-Engel; Martin Kerwer; Andreas G Klein
Journal:  Front Psychol       Date:  2014-03-04
View more
  15 in total

1.  Patient-Reported Outcome Measures in Routine Clinical Care: The PROMise of a Better Future?

Authors:  Hayley A Hutchings; Laith Alrubaiy
Journal:  Dig Dis Sci       Date:  2017-08       Impact factor: 3.199

2.  Cohort Profile: The Christchurch IBS cOhort to investigate Mechanisms FOr gut Relief and improved Transit (COMFORT).

Authors:  Phoebe Heenan; Rob H Creemers; Shriya Sharma; Jacqueline Keenan; Simone Bayer; Wayne Young; Janine Cooney; Kelly Armstrong; Karl Fraser; Paula M Skidmore; Nicholas J Talley; Nicole Roy; Richard B Gearry
Journal:  Inflamm Intest Dis       Date:  2020-07-08

3.  Functional Disease, Dysbiosis, and Dyspepsia: How Helpful Is Rifaximin?

Authors:  Sridhar Sundaram; Harish Darak
Journal:  Dig Dis Sci       Date:  2021-08-14       Impact factor: 3.487

4.  Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors.

Authors:  Moritz von Wulffen; Nicholas J Talley; Johann Hammer; Jessica McMaster; Graeme Rich; Ayesha Shah; Natasha Koloski; Bradley J Kendall; Mike Jones; Gerald Holtmann
Journal:  Dig Dis Sci       Date:  2018-10-27       Impact factor: 3.199

5.  Habitual Green Kiwifruit Consumption Is Associated with a Reduction in Upper Gastrointestinal Symptoms: A Systematic Scoping Review.

Authors:  Simone B Bayer; Chris M Frampton; Richard B Gearry; Giovanni Barbara
Journal:  Adv Nutr       Date:  2022-06-01       Impact factor: 11.567

Review 6.  Improving Quality of Care in Patients with Liver Cirrhosis.

Authors:  Mehdi Saberifiroozi
Journal:  Middle East J Dig Dis       Date:  2017-10

7.  Functional gastrointestinal and somatoform symptoms five months after SARS-CoV-2 infection: A controlled cohort study.

Authors:  Daniele Noviello; Andrea Costantino; Antonio Muscatello; Alessandra Bandera; Dario Consonni; Maurizio Vecchi; Guido Basilisco
Journal:  Neurogastroenterol Motil       Date:  2021-06-01       Impact factor: 3.960

8.  Effects of taurocholic acid metabolism by gut bacteria: A controlled feeding trial in adult African American subjects at elevated risk for colorectal cancer.

Authors:  Patricia G Wolf; H Rex Gaskins; Jason M Ridlon; Sally Freels; Alyshia Hamm; Sarah Goldberg; Phyllis Petrilli; Teresa Schering; Sevasti Vergis; Sandra Gomez-Perez; Cemal Yazici; Carol Braunschweig; Ece Mutlu; Lisa Tussing-Humphreys
Journal:  Contemp Clin Trials Commun       Date:  2020-07-08

9.  A randomized controlled study for Yuanhu Zhitong dropping pills in the treatment of knee osteoarthritis.

Authors:  Yubiao Gu; Jin Huang; Honggang Guo; Xuewen Song; Jianguo Li; Yanlong Shi; Xingwen Xie
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

Review 10.  "It ain't over … till it's over!" Risk-mitigation strategies for patients with gastrointestinal diseases in the aftermath of the COVID-19 pandemic.

Authors:  Gerald Holtmann; Eamonn M Quigley; Ayesha Shah; Michael Camilleri; Victoria Py Tan; Kok Ann Gwee; Kentaro Sugano; Jose D Sollano; Kwong M Fock; Uday C Ghoshal; Minhu Chen; Axel Dignass; Henry Cohen
Journal:  J Gastroenterol Hepatol       Date:  2020-06-29       Impact factor: 4.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.